Clinical Trials Browser

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT05298683 2022-03-28

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

Phase 2 Unknown

108 enrolled

Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Paraproteinemias, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02424851 2022-01-27

OPTIMAL

Phase 2 Completed

31 enrolled 13 charts

Plasma cell

Multiple Myeloma, Renal Insufficiency, Chronic, Renal Insufficiency, Neoplasms, Plasma Cell

NCT02045017 2021-08-27

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Phase 2 Completed

81 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT01337752 2020-12-17

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Phase 2 Completed

9 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT01447914 2019-08-28

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Phase 2 Completed

16 enrolled 11 charts

Classical hematologyOther hematologic neoplasmPlasma cell

Amyloidosis, Anemia, Bone Diseases, Metabolic, Fractures, Spontaneous, Hypercalcemia, Multiple Myeloma, Osteolysis, Paraproteinemias, Hematologic Neoplasms, Renal Insufficiency

NCT01270932 2017-12-29

Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients

Phase 2 Completed

28 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT00721734 2017-05-02

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Phase 2 Completed

50 enrolled 33 charts

Plasma cell

Multiple Myeloma, Renal Insufficiency, Neoplasms, Plasma Cell

NCT00779922 2016-10-11

Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

Phase 2 Completed

39 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT01084837 2015-09-17

RENVEL

Phase 2 Completed

60 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

NCT00401804 2013-01-24

Bortezomib-Dexamethasone-Doxorubicin-Study

Phase 2 Completed

72 enrolled

Plasma cell

Multiple Myeloma, Renal Insufficiency

Clinical Trials

VICD

Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

BRIDGE

A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

A Phase 2 Study of Isatuximab in Combination With Pomalidomide and Dexamethasone in MM Patients Who Received One Prior Line of Therapy Containing Lenalidomide and a Proteasome Inhibitor

OPTIMAL

Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

Tivantinib in Treating Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

Lenalidomide & High Dose Dexamethasone for Untreated Multiple Myeloma Renal Failure Patients

Study of the Safety and Pharmacokinetics of Carfilzomib in Patients With Relapsed and Refractory Multiple Myeloma and Varying Degrees of Renal Function

Pharmacokinetics of Lenalidomide (Revlimid®) in Patients With Multiple Myeloma and Impaired Renal Function

RENVEL

Bortezomib-Dexamethasone-Doxorubicin-Study